{
    "eid": "2-s2.0-85056577463",
    "title": "Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: A network meta-analysis",
    "cover-date": "2018-11-14",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Antiviral",
        "Hepatitis B",
        "HIV",
        "Network meta-analysis"
    ],
    "authors": [
        "Cho Naing",
        "Yong Poovorawan",
        "Kew Siang Tong"
    ],
    "citedby-count": 3,
    "ref-count": 54,
    "ref-list": [
        "Comparative biology and pathogenesis of AIDS and hepatitis B viruses: Related but different",
        "HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter AIDS cohort study (MACS)",
        "Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort",
        "Epidemiology of viral hepatitis and HIV co-infection",
        "Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?",
        "Hepatitis B and human immunodeficiency virus coinfection",
        "Preventing and treating hepatitis B infection",
        "Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus:an open-label pilot study",
        "Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial",
        "Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool",
        "The PRISMA extension for network meta-analysis: Bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses",
        "Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). the CAESAR Coordinating Committee",
        "Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand",
        "Cochrane Bias methods group; Cochrane Statistical Methods Group the Cochrane Collaboration's tool for assessing risk of bias in randomised trials",
        "GRADE: An emerging consensus on rating quality of evidence and strength of recommendations",
        "GRADE guidelines: 5. Rating the quality of evidence - Publication bias",
        "Network meta-analysis: Application and practice using Stata",
        "GRADE guidelines: 3. Rating the quality of evidence",
        "Graphical tools for network meta-analysis in STATA",
        "Consistency and inconsistency in network meta-analysis: Model estimation using multivariate meta-regression",
        "Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis",
        "Evaluating the quality of evidence from a network meta-analysis",
        "Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus",
        "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127",
        "A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand",
        "Emergence of lamivudine-resistant hbv during antiretroviral therapy including lamivudine for patients coinfected with HIV and HBV in China",
        "Hepatitis B virus (HBV) load response to 2 antiviral regimens, tenofovir/lamivudine and lamivudine, in HIV/HBV-coinfected pregnant women in Guangxi, China: The Tenofovir in pregnancy (TiP) study",
        "Hepatitis B virus infection and response to antiretroviral therapy (ART) in a south African ART program",
        "Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine",
        "Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIVHBV-coinfected patients",
        "Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection",
        "Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort",
        "Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria",
        "Virologic outcome of using tenofovir/emtricitabine to treat hepatitis b in hiv-coinfected patients",
        "Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa",
        "Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials",
        "Quantitative HBsAg and HBeAg predict hepatitis b seroconversion after initiation of HAARTt in HIV-HBV coinfected individuals",
        "Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort",
        "Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study",
        "Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study",
        "Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients",
        "Lamivudine monotherapy-based cart is efficacious for HBV treatment in hiv/HBV coinfection when baseline HBV DNA <20,000 IU/mL",
        "Approaches to interpreting and choosing the best treatments in network meta-analyses",
        "Management of Antiviral Resistance in chronic hepatitis B",
        "No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B",
        "Considerations for antiretroviral use in patients with coinfections",
        "Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data en HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis",
        "Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta-analyses",
        "Suppression of HBV by tenofovir in HBV/HIV Coinfected patients: A systematic review and meta-analysis",
        "Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013",
        "Treatment predictors of a sustained virologic response in hepatitis B and C"
    ],
    "affiliation": [
        {
            "affiliation-city": "Townsville",
            "@id": "60019870",
            "affilname": "James Cook University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019870",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60001508",
            "affilname": "International Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001508",
            "affiliation-country": "Malaysia"
        }
    ],
    "funding": [
        "International Medical University"
    ]
}